Last reviewed · How we verify

NCT06882824: HEMOMYOC

Prevention of HEMOrhagic Risk in Upper MYOmeCTomy by Use of Misoprostol.

Recruiting now NA Last updated 24 September 2025
What this trial tests

NA trial testing myomectomy with placebo in Myoma;Uterus in 80 participants. Currently enrolling.

Timeline
12 March 2025
Primary endpoint
17 April 2027
17 April 2028

Quick facts

Lead sponsorUniversity Hospital, Clermont-Ferrand
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment80
Start date12 March 2025
Primary completion17 April 2027
Estimated completion17 April 2028
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Clermont-Ferrand

Who can join

Adults 18 to 43, female only, with Myoma;Uterus or Myomectomy; Surgical Blood Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In France, uterine fibroids or leiomyomas are the most common benign tumour in women of childbearing age. In 30% of cases, fibroids are symptomatic (menorrhagia, anaemia, pain), in which case surgical management is indicated. This is known as myomectomy, and can be performed by hysteroscopy, laparoscopy (laparoscopy) or laparotomy, depending on the number, size and position of the fibroids. Intraoperative bleeding is the main surgical difficulty. For this reason, a number of studies have focused on ways of minimizing the risk of bleeding. A good surgical indication, prevention of anaemia (iron deficiency) and transient occlusion of the uterine arteries during surgery help to reduce this risk. There are also drugs available to reduce intraoperative bleeding, but few studies have been carried out to assess their real effectiveness. One such product is Misoprostol, commonly used in gynecology. Its muscle-contracting properties suggest that it could have a beneficial effect on bleeding during surgery. What's more, this treatment has been used for many years and is reputed to be very well tolerated. The most frequent side effects are digestive, with a risk of abdominal pain in the form of cramps, nausea or vomiting. The investigators therefore decided to set up the HEMOMYOC study to demonstrate a significant reduction in bleeding during laparotomy or laparoscopic myomectomy after taking oral misoprostol in combination with transient occlusion of the uterine arteries, compared with placebo. It would seem that the ease of use and good tolerance of misoprostol, in combination with transient occlusion of the uterine arteries, could be of real benefit in preventing intraoperative morbidity in myomectomies, whatever the surgical approach. To date, no studies have been carried out in this area.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myoma;Uterus

Currently open trials in the same condition.

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06882824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing